Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-464-937"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-464-937"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-464-9522
lpv:speaker	lp:Sergio Paolo Francesco Silvestris2
lpv:spokenAs	substitute; BUDG (2012-01-19--2014-06-30)3 member; AGRI (2012-01-19--2014-06-30)3 substitute; Delegation for relations with Albania, Bosnia and Herzegovina, Serbia, Montenegro and Kosovo (2009-09-16--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 member_of_the_bureau; EPP (2012-02-03--2014-06-30)3 unknown; Il Popolo della Libertà (2009-07-14--2013-12-11)3 member; Delegation for relations with the Maghreb countries and the Arab Maghreb Union (2009-09-16--2014-06-30)3
lpv:translated text	"The European Medicines Agency (EMA) protects and promotes public and animal health through the evaluation and supervision of medicinal products for human and veterinary use. All medicinal products for human and animal use derived from biotechnology and other high-technology processes must be approved via the centralised procedure. The same applies to all human medicines intended for the treatment of HIV/AIDS, cancer, diabetes or neurodegenerative diseases and for all designated orphan medicines intended for the treatment of rare diseases. The Agency is also involved in referral procedures relating to medicinal products that are approved or under consideration by Member States. I voted in favour of closing the accounts of the European Medicines Agency for the financial year 2010."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph